A Phase II Trial of Perioperative Camrelizumab Plus Neoadjuvant Chemotherapy in Resectable Stage IIB–IIIB Lung Squamous Cell Carcinoma

ABSTRACT This phase II trial investigated perioperative camrelizumab plus neoadjuvant chemotherapy for patients with stage IIB–IIIB lung squamous cell carcinoma (LUSC) and explored predictive biomarkers of treatment response. Patients received neoadjuvant camrelizumab (200 mg, Day 1) in combination...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Mingming Hu, Shuku Liu, Yi Han, Feng Wang, Yang Liu, Baohua Lu, Hongxia Li, Yuan Gao, Ying Wang, Wei Yang, Kang Shi, Bo Xiao, Qunhui Wang, Juan Du, Haifeng Lin, Xiaomi Li, Chong Wang, Tongmei Zhang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2026-07-01
Colecção:	MedComm
Assuntos:	camrelizumab lung squamous cell carcinoma major pathological response neoadjuvant immunochemotherapy perioperative immunotherapy
Acesso em linha:	https://doi.org/10.1002/mco2.70793
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!